Cargando…
Market Withdrawal of Vioxx: Is it Time to Retihink the Use of COX-2 Inhibitors?
On September 30, 2004, Merck and Co. Inc., the manufacturer of the arthritis drug rofecoxib (Vioxx), announced the worldwide voluntary market withdrawal of rofecoxib after a study confirmed long-standing concerns that use of the drug raises the risk of heart attack and stroke.1 The drug was aggressi...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2004
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437429/ https://www.ncbi.nlm.nih.gov/pubmed/15548128 http://dx.doi.org/10.18553/jmcp.2004.10.6.551 |